🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are seen in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options presently on offer.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in recent days for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts believe that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This milestone marks a huge turning point in the management of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Results and Worldwide Availability

Based on results released by a prominent scientific publication, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines a dual-drug approach. The study enrolled hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of developing nations.

Medical professionals on the front lines have expressed hope. The availability of a easy-to-administer therapy like this is described as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.